David Grainger | |
---|---|
Born | 12 October 1966 |
Alma mater | Cambridge University |
Occupation(s) | venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger |
David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm [1] and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space. [2] [3]
He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco, [4] in the firm's life sciences practice. He also writes for Forbes.com on topics related to the pharmaceutical industry. [5]
Reared in England, Grainger graduated with degree in Natural Sciences ( Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992. [6]
After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University. [7] Following publications in Nature [8] and elsewhere [9] setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system, [10] Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997. [11]
While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001), [12] and Funxional Therapeutics (2005). [13] FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006. [12] [14] Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer [13] until it was sold to Boehringer Ingelheim in 2012. [15]
Grainger joined Index Ventures in 2012, [16] and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”. [17] where he was involved with funding and advising a variety of companies, including XO1, [18] a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson [19] [20] [21] He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier. [1] [22]
Grainger has co-authored a number of papers in peer-reviewed scientific journals, [23] including Nature, [8] Science [24] and Nature Medicine. [25]
Grainger formerly blogged under the pen name “DrugBaron” on a range of topics related to the pharmaceutical industry, [26] and now has a column on similar topics on Forbes.com. [5]
David Grainger | |
---|---|
Born | 12 October 1966 |
Alma mater | Cambridge University |
Occupation(s) | venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger |
David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm [1] and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space. [2] [3]
He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco, [4] in the firm's life sciences practice. He also writes for Forbes.com on topics related to the pharmaceutical industry. [5]
Reared in England, Grainger graduated with degree in Natural Sciences ( Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992. [6]
After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University. [7] Following publications in Nature [8] and elsewhere [9] setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system, [10] Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997. [11]
While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001), [12] and Funxional Therapeutics (2005). [13] FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006. [12] [14] Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer [13] until it was sold to Boehringer Ingelheim in 2012. [15]
Grainger joined Index Ventures in 2012, [16] and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”. [17] where he was involved with funding and advising a variety of companies, including XO1, [18] a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson [19] [20] [21] He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier. [1] [22]
Grainger has co-authored a number of papers in peer-reviewed scientific journals, [23] including Nature, [8] Science [24] and Nature Medicine. [25]
Grainger formerly blogged under the pen name “DrugBaron” on a range of topics related to the pharmaceutical industry, [26] and now has a column on similar topics on Forbes.com. [5]